Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > American Pharmaceutical Partners Reports Tolerability of High Dose

June 8th, 2004

American Pharmaceutical Partners Reports Tolerability of High Dose

Abstract:
Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. today reported results of a Phase I dose-escalation study of ABRAXANETM (albumin nanoparticle paclitaxel) that indicated this investigational drug is well-tolerated at high doses in a weekly dosing schedule for non-hematologic malignancies such as lung, ovarian and metastatic breast cancer and patients who have had prior chemotherapies.

Source:
APP

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

How to power up graphene implants without frying cells: New analysis finds way to safely conduct heat from graphene to biological tissues September 30th, 2016

Nanosensors could help determine tumors’ ability to remodel tissue: Measuring enzyme levels could help doctors select appropriate treatments September 29th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic